Sponsor pipeline

Calcilytix Therapeutics, Inc., a BridgeBio company clinical trial pipeline

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Phase 2/3		1
Phase 3		2

Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

NCT ID	Title	Condition	Status	Updated
Phase 3
NCT07805356	Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic…	Hypoparathyroidism	Recruiting	2026-09-16
NCT05680818	Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1	Autosomal Dominant Hypocalcemia (ADH)	Active, Not Recruiting	2026-07-29
Phase 2/3
NCT07080385	Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With…	Autosomal Dominant Hypocalcemia Type 1 (ADH1)	Recruiting	2026-04-22
Not specified
NCT05227287	ADH1 and ADH2 Disease Monitoring Study (DMS)	Autosomal Dominant Hypocalcemia	Active, Not Recruiting	2026-04-30

Get alerts when Calcilytix Therapeutics, Inc., a BridgeBio company's trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.